A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach

Francesco Lanza, Francesco Saraceni, Annalisa Pezzi, Massimo Martino, Alberto Bosi, Nicola Cascavilla, Pellegrino Musto, Eliana Zuffa, Monica Tani, Claudia Cellini, Daniele Laszlo, Francesca Bonifazi

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)E557-E559
JournalAmerican Journal of Hematology
Volume92
Issue number9
DOIs
Publication statusPublished - Sep 2017

Keywords

  • Biosimilar Pharmaceuticals/administration & dosage
  • Blood Cell Count
  • Filgrastim/administration & dosage
  • Hematopoietic Stem Cell Mobilization
  • Heterocyclic Compounds/administration & dosage
  • Humans
  • Lymphoma, Non-Hodgkin/blood
  • Multiple Myeloma/blood
  • Propensity Score
  • Retrospective Studies

Cite this